Safe and effective iron supplementation in malaria endemic areas

Towards safe and effective iron supplementation in malaria endemic areas: randomized double-blind placebo controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83091970

Enrollment

350

Registered

2012-05-16

Start date

2011-07-28

Completion date

Unknown

Last updated

2017-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, malaria and geohelminths Haematological Disorders Iron deficiency anaemia

Interventions

400 mg albendazole per day orally for three consecutive days in combination with iron supplementation or matching placebo 6 mg/kg body weight for 6 days/week for total duration 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Those who have given informed consent 2. Both males and females 3. Aged between 6-18 years old 4. Malarial parasitemia negative by microscopy 5. Hemoglobin (Hb) > 8 g/dl 6. Hb = 7 years 8. Hb =7 years

Exclusion criteria

Exclusion criteria: Clinical symptoms indicating malaria or any severe underlying condition

Design outcomes

Primary

Measure	Time frame
Microscopic and submicroscopic incidence of malaria	—

Secondary

Measure	Time frame
1. Changes in hemoglobin levels 2. Iron parameters (ferritin, sTFR) 3. Endothelial cells markers (ICAM-1 and Vwf) 4. C-reactive protein (CRP)	—

Countries

Indonesia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026